D'Amato R F, Wallman A A, Hochstein L H, Colaninno P M, Scardamaglia M, Ardila E, Ghouri M, Kim K, Patel R C, Miller A
Department of Pathology, Catholic Medical Center of Brooklyn and Queens, Jamaica, New York 11432, USA.
J Clin Microbiol. 1995 Jul;33(7):1832-4. doi: 10.1128/jcm.33.7.1832-1834.1995.
A rapid PCR-based test for the diagnosis of pulmonary tuberculosis, the Roche AMPLICOR Mycobacterium tuberculosis test (AMPLICOR MTB), was evaluated. Results from AMPLICOR MTB were compared with culture results and the final clinical diagnosis for each patient. A total of 985 specimens from 372 patients were tested. When AMPLICOR MTB results were compared with resolved results, i.e., a specimen grew M. tuberculosis or was obtained from a patient with a clinical diagnosis of tuberculosis, the sensitivity, specificity, positive predictive value, and negative predictive value for the AMPLICOR MTB test were 66.7, 99.6, 91.7, and 97.7%, respectively. These results were comparable to those obtained from culture. Test results were available approximately 6.5 h after specimen receipt in the laboratory. Our data demonstrate that AMPLICOR MTB will provide rapid, valuable information for the diagnosis and control of tuberculosis.
对一种基于聚合酶链反应（PCR）的快速检测方法——罗氏AMPLICOR结核分枝杆菌检测（AMPLICOR MTB）进行了评估，用于诊断肺结核。将AMPLICOR MTB检测结果与培养结果以及每位患者的最终临床诊断结果进行了比较。共对372例患者的985份标本进行了检测。当将AMPLICOR MTB检测结果与确诊结果进行比较时，即标本培养出结核分枝杆菌或取自临床诊断为结核病的患者，AMPLICOR MTB检测的敏感性、特异性、阳性预测值和阴性预测值分别为66.7%、99.6%、91.7%和97.7%。这些结果与培养结果相当。在实验室收到标本后约6.5小时即可获得检测结果。我们的数据表明，AMPLICOR MTB将为结核病的诊断和控制提供快速、有价值的信息。
